Author

Thean Hsiang Tan

Observed names: T. Hsiang Tan, T.H. Tan, Thean H. Tan, Thean Hsiang, Thean Hsiang TAN, Thean Tan

Institutions: Royal Adelaide Hospital, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, The University of Adelaide

Observed institutions: Australian National University, The University of Sydney, Royal Adelaide Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Canberra Hospital, Chris O’Brien Lifehouse, Eastern Health, Monash Health, Waikato District Health Board, Australian and New Zealand Urogenital and Prostate Cancer Trials Group, ACT Government, Monash University, The University of Adelaide

OpenAlex ID: A5110503703

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

2019 · Ian D. Davis, Andrew J. Martin, et al. · New England Journal of Medicine · 1,660

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

2021 · Michael S Hofman, Louise Emmett, et al. · The Lancet · 1,209

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 367

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

2022 · James P Buteau, Andrew J Martin, et al. · The Lancet Oncology · 309

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

2023 · Michael S Hofman, Louise Emmett, et al. · The Lancet Oncology · 240

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

2023 · Christopher J Sweeney, Andrew J Martin, et al. · The Lancet Oncology · 214

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

2024 · Louise Emmett, Shalini Subramaniam, et al. · The Lancet Oncology · 204

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

2017 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet · 172

PDF

Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases

2013 · Andrea M. Stringer, Noor Al-Dasooqi, et al. · Supportive Care in Cancer · 136

Noncardiac Vascular Toxicities of Vascular Endothelial Growth Factor Inhibitors in Advanced Cancer: A Review

2011 · Dorothy Keefe, Joanne Bowen, et al. · The Oncologist · 93

PDF

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

2019 · Daniel P Petrylak, Ronald de Wit, et al. · The Lancet Oncology · 87

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

2025 · Louise Emmett, Shalini Subramaniam, et al. · The Lancet Oncology · 86

TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).

2020 · Michael S Hofman, Louise Emmett, et al. · Journal of Clinical Oncology · 65

Radioembolization in Combination with Systemic Chemotherapy as First-line Therapy for Liver Metastases from Colorectal Cancer

2011 · Suzanne Kosmider, Thean H. Tan, et al. · Journal of Vascular and Interventional Radiology · 65

2021 · Martin R. Stockler, Andrew J. Martin, et al. · Journal of Clinical Oncology · 61

PDF

TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).

2022 · Michael S Hofman, Louise Emmett, et al. · Journal of Clinical Oncology · 55

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).

2022 · Ian D. Davis, Andrew James Martin, et al. · Journal of Clinical Oncology · 54

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

2021 · Christopher J. Sweeney, Andrew J. Martin, et al. · European Urology · 53

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

2025 · Edmond M. Kwan, Sarah W. S. Ng, et al. · Nature Medicine · 49

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

2025 · Louise Emmett, Nathan Papa, et al. · The Lancet Oncology · 39

Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).

2023 · Shahneen Sandhu, Shalini Subramaniam, et al. · Journal of Clinical Oncology · 27

Medical management of metastatic prostate cancer

2018 · Amy Body, Ganes Pranavan, et al. · Australian Prescriber · 15

PDF

Rare and Novel Epidermal Growth Factor Receptor Mutations in Non—Small-Cell Lung Cancer and Lack of Clinical Response to Gefitinib in Two Cases

2012 · Amit Sharma, Thean H. Tan, et al. · Journal of Thoracic Oncology · 14

177 Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).

2025 · Shahneen Sandhu, Shalini Subramaniam, et al. · Journal of Clinical Oncology · 13

PDF

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304).

2025 · Alison Yan Zhang, Ian D. Davis, et al. · Journal of Clinical Oncology · 12

PDF

Works count: 51

Citation count: 6,580

H-index: 22

I10-index: 27